The amylin receptor as a novel therapeutic target for Alzheimer's disease

胰淀素受体作为阿尔茨海默病的新治疗靶点

• 批准号: 351841
• 负责人: Jhamandas Jack H
• 金额: $ 7.29万
• 依托单位: University of Alberta
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2016
• 资助国家: 加拿大
• 起止时间: 2016-04-01 至 2017-04-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=351841&lang=en
• 关键词: Alzheimer'S Disease; Amylin Peptide/Receptor; Amyloid Protein; Behavioural Testing; Cellular Neurophysiology; Long Term Potentiation (Ltp); Molecular Biology; Transgenic Mice

Alzheimer's disease and diabetes mellitus, two of the most serious public health concerns of our times share many commonalities. In Alzheimer's disease, abnormal deposition of the amyloid protein in the brain is linked to destruction and death of brain ce

阿尔茨海默病和糖尿病是我们时代两个最严重的公共卫生问题，它们有许多共同点。在阿尔茨海默氏病中，大脑中淀粉样蛋白的异常沉积与脑细胞的破坏和死亡有关。